Scientists probe gut hormones to unlock diabetes mystery in cystic fibrosis

NCT ID NCT01851694

Recruiting now Knowledge-focused Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to understand why many people with cystic fibrosis develop diabetes. Researchers will give two gut hormones, GLP-1 and GIP, to 45 adults with cystic fibrosis and measure how their pancreas releases insulin. The goal is to learn more about cystic fibrosis-related diabetes and find better ways to treat it in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 and GIP (hormones that boost insulin)
What this could lead to: If successful, this research could point toward new treatment options for cystic fibrosis-related diabetes.
What could go wrong: This is an early-stage observational study with only 45 participants, so results may not apply to everyone. It aims to understand the disease, not test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis cystic fibrosis-related diabetes diabetes mellitus exocrine pancreatic insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS PANCREATIC INSUFFICIENCY

Contacts and locations

Locations

Children's Hospital of Philadelphia and University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19060, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.